Study Summary
This trial will study a potential new treatment, ASP2074, for people with certain solid tumors who have already tried standard treatments. They will be given different doses to find the most suitable one, and monitored for any medical problems from the treatment.
- Advanced Solid Tumors
Treatment Effectiveness
Effectiveness Progress
Study Objectives
6 Primary · 13 Secondary · Reporting Duration: Up to 21 Months
Trial Safety
Safety Progress
Trial Design
4 Treatment Groups
ASP2074 Dose Escalation (Part 1)
1 of 4
ASP2074 Dose Expansion (Part 2) Colorectal Adenocarcinoma
1 of 4
ASP2074 Dose Expansion (Part 2) Esophageal or GEJ Adenocarcinoma
1 of 4
ASP2074 Dose Expansion (Part 2) Pancreatic Adenocarcinoma
1 of 4
Experimental Treatment
193 Total Participants · 4 Treatment Groups
Primary Treatment: ASP2074 Dose Escalation (Part 1) · No Placebo Group · Phase 1
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 9 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
Is it possible for new participants to register for this research endeavor?
"This research study is currently recruiting patients, as noted on clinicaltrials.gov. It was first posted to the website and last updated in February of 2023." - Anonymous Online Contributor
To what extent can ASP2074 Dose Escalation (Part 1) be perilous to individuals?
"ASP2074 Dose Escalation (Part 1) has a safety rating of 1, due to the limited data available on its efficacy and level of risk. This is an early-stage trial." - Anonymous Online Contributor
How many participants have been enrolled in this clinical experiment?
"Affirmative. The records on clinicaltrials.gov verify that this medical trial is presently soliciting participants, which it originally advertised starting January 25th 2023 and adjusted most recently February 20th of the same year. 193 individuals are required to register from a solitary location." - Anonymous Online Contributor
What is the desired outcome of this experiment?
"This clinical trial intends to measure the number of Adverse Events experienced by participants over a 28-day period, with secondary objectives including an assessment of Objective Response Rates (ORR) according to iRECIST and RECIST v1.1 criteria along with Duration of Response (DOR)." - Anonymous Online Contributor